These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29045452)

  • 1. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
    Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
    PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
    Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
    Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
    Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A
    Curr Med Res Opin; 2015 Jun; 31(6):1129-37. PubMed ID: 25851308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
    Erber R; Angeloni M; Stöhr R; Lux MP; Ulbrich-Gebauer D; Pelz E; Bankfalvi A; Schmid KW; Walter RFH; Vetter M; Thomssen C; Mayr D; Klauschen F; Sinn P; Sotlar K; Stering K; Stenzinger A; Wunderle M; Fasching PA; Beckmann MW; Hoffmann O; Kimmig R; Harbeck N; Wuerstlein R; Ferrazzi F; Hartmann A
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).
    Ohnstad HO; Blix ES; Akslen LA; Gilje B; Raj SX; Skjerven H; Borgen E; Janssen EAM; Mortensen E; Brekke MB; Falk RS; Schlichting E; Boge B; Songe-Møller S; Olsson P; Heie A; Mannsåker B; Vestlid MA; Kursetgjerde T; Gravdehaug B; Suhrke P; Sanchez E; Bublevic J; Røe OD; Geitvik GA; Halset EH; Rypdal MC; Langerød A; Lømo J; Garred Ø; Porojnicu A; Engebraaten O; Geisler J; Lyngra M; Hansen MH; Søiland H; Nakken T; Asphaug L; Kristensen V; Sørlie T; Nygård JF; Kiserud CE; Reinertsen KV; Russnes HG; Naume B
    ESMO Open; 2024 Jun; 9(6):103475. PubMed ID: 38838499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
    Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
    Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
    Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
    Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
    Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
    Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
    Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
    Abdelhakam DA; Hanna H; Nassar A
    Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
    Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
    Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
    Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
    Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
    Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Rasmussen BB; Knoop AS; Buckingham W; Ferree S; Schaper C; Nielsen TO; Haffner T; Kibøl T; Møller Talman ML; Bak Jylling AM; Tabor TP; Ejlertsen B
    J Clin Oncol; 2018 Mar; 36(8):735-740. PubMed ID: 29369732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
    Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.